Immunoliposome Development Service

Advances in protein engineering have revolutionized nanomedicine by introducing new nanocarriers to deliver cancer therapeutics. Designing components that simultaneously combine therapeutic agents and targeted disease sites has been the focus of recent research. Such devices have been developed to respond dynamically to certain cues that trigger drug release. Immunoliposomes have been considered as attractive drug targeting carriers for cancer treatment. Creative Biolabs provides customers with professional immunoliposome customization services to solve customer problems.

Background of Immunoliposome

IgG immunoglobulins and their fragments (fragment antigen binding (Fab) or single chain variable fragment (scFV)) are the most widely studied ligands for targeted therapy and diagnosis of tumors through drug-loaded liposomes. After they were first described in the 1980s, several promising tumor targeting studies related to immunoliposomes have been carried out. Antibodies can be covalently and non-covalently attached to liposomes to form immunoliposomes, which combine antibody-mediated tumor recognition and liposome delivery, aiming at target cell internalization and intracellular drug release.

Fig.1 Strategies to conjugate monoclonal antibodies or their fragments to liposomes

Features of Immunoliposome

After binding to tumor cells, immunoliposome-encapsulated drugs can be delivered through four different mechanisms: (1) adsorption to the cell surface; (2) fusion with the cell membrane; (3) exchange of lipid components with the cell membrane; and (4) pathway of endocytosis. For receptor-mediated endocytosis, drug-containing nanocarriers must be able to penetrate the inside of the cell and bypass lysosomal degradation in order to effectively target the intracellular compartment.

Generally, the ability of antibody-targeted liposomes to increase the concentration of bioavailable drugs depends on the release rate of the entrapped drug from the liposome at the target site. The ideal intelligent immunoliposome carrier should specifically aggregate in the target tissue and have the ability to "turn on" certain functions under the action of biological stimulation. This stimulus can be inherent to the diseased area, such as changes in enzyme levels, pH, and temperature (characterized by inflammation and tumor areas), or external stimuli, such as magnetic fields, ultrasound, light, and heat. These new methods of changing the tumor microenvironment can avoid complications related to receptor-specific targeting and provide new insights for better treatment effects.

What We Can Do about Immunoliposome Liposome Development?

Immunoliposomes provide a complementary and advantageous drug delivery strategy for antibody drug conjugates in many cases. In the development of immunoliposomes, Creative Biolabs optimizes every step as much as possible, including antibody production, coupling, liposome formulation and drug loading, in order to meet the needs of different clients. If you are interested in our service, please feel free to contact us.

For Research Use Only. Not For Clinical Use